8-K current report · filed Oct 14, 2026

Rezolute, Inc. (RZLT) 8-K Current Report: October 14, 2026

Item 7.01Item EX-99.1RZLT overview

Short answer

Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Rezolute announced an upLIFT study patient-enrollment update on October 14, 2026.

Rezolute, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Rezolute announced an upLIFT study patient-enrollment update on October 14, 2026
  • Enrollment progress is material because it affects trial timelines and potential future clinical readouts
  • Investors need Exhibit 99.1 for the substantive enrollment details and any revised expectations
  • Disclosure includes forward-looking statements, increasing uncertainty around timing and study outcomes

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 upLIFT enrollment complete, with topline results expected mid-December 2026
  • Trial includes 16 participants with tumor hyperinsulinism and uncontrolled hypoglycemia requiring intravenous glucose
  • Primary endpoint requires at least 50% reduction in glucose infusion rate, with statistical success requiring at least 56% responders
  • Interim cohort showed 7 of 8 responders, each discontinuing intravenous glucose, supporting potential efficacy ahead of topline data
  • Ersodetug was well-tolerated so far, but remains investigational and regulatory approval is not assured

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Rezolute, Inc. 8-K filings

Get the next RZLT 8-K as it lands

Follow RZLT for push alerts, or ask the research agent what this filing means.